Deltex Medical Group plc, the haemodynamic monitoring company, has announced the first case study of the non-invasive SupraQ monitor being used to guide successful intervention in a critically ill patient.
In order to resuscitate this patient, the entirely non-invasive SupraQ was used instead of a combination of invasive central venous pressure (CVP) and peripheral arterial catheters. In this case, to insert a CVP would have required the administration of clotting factors and platelets, a procedure which normally takes up to two hours.
Using the SupraQ allowed the clinicians to quickly and accurately resuscitate this patient in a non-invasive manner.
The SupraQ allowed doctors to haemodynamically optimise the patient more quickly, more safely and more accurately than would have been possible with traditional invasive pressure monitoring. Failure to successfully fluid resuscitate such patients is associated with significantly increased risk of death. Early resuscitation has been shown to improve outcome.
Dr Graeme Sanders, consultant in anaesthesia at the Medway Maritime Hospital, said: “Using the non-invasive SupraQ allowed us to treat this critically ill patient quickly and accurately. It’s the first time we have used the device in a critical care setting – it made a real difference to the care we could offer”.
